Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
UTHR — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

5.1

Margin Of Safety %

-1

Put/Call OI Ratio

0.66

EPS Next Q Diff

-0.22

EPS Last/This Y

-3.21

EPS This/Next Y

4.59

Price

538.83

Target Price

664.33

Analyst Recom

1.5

Performance Q

-5.33

Upside

14.2%

Beta

0.56

Ticker: UTHR




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13UTHR535.411.522.6917486
2026-07-14UTHR526.641.530.8817628
2026-07-15UTHR531.971.536.0617650
2026-07-16UTHR528.681.537.3517667
2026-07-17UTHR535.671.511.3217840
2026-07-20UTHR528.831.700.1517279
2026-07-21UTHR535.481.692.1317380
2026-07-22UTHR527.071.6917.7717527
2026-07-23UTHR529.631.808.6718297
2026-07-24UTHR528.331.811.4218398
2026-07-27UTHR527.771.816.2218436
2026-07-28UTHR523.421.821.1418475
2026-07-29UTHR524.771.82274.8618485
2026-07-30UTHR525.741.091.1713716
2026-07-31UTHR517.461.090.2613987
2026-08-03UTHR516.271.090.2114003
2026-08-04UTHR518.591.091.5414127
2026-08-05UTHR519.381.094.9614739
2026-08-06UTHR532.791.120.5315211
2026-08-07UTHR538.830.660.2844721
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13UTHR535.419.9- 27.28
2026-07-14UTHR526.279.9- 26.85
2026-07-15UTHR531.789.9- 26.85
2026-07-16UTHR528.689.9- 26.85
2026-07-17UTHR535.399.9- 26.85
2026-07-20UTHR529.599.9- 26.85
2026-07-21UTHR535.779.9- 26.85
2026-07-22UTHR527.029.9- 26.85
2026-07-23UTHR529.419.9- 26.85
2026-07-24UTHR528.299.9- 26.85
2026-07-27UTHR527.709.8- 26.91
2026-07-28UTHR523.429.6- 26.92
2026-07-29UTHR524.669.6- 26.92
2026-07-30UTHR526.079.6- 26.92
2026-07-31UTHR517.469.6- 26.92
2026-08-03UTHR516.429.6- 26.92
2026-08-04UTHR516.429.6- 26.92
2026-08-05UTHR518.709.6- 26.92
2026-08-06UTHR532.679.6- 26.92
2026-08-07UTHR538.830.0- 26.92
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13UTHR-48.410.105.17
2026-07-14UTHR-47.960.105.17
2026-07-15UTHR-48.130.105.17
2026-07-16UTHR-48.370.105.17
2026-07-17UTHR-48.690.105.17
2026-07-20UTHR-48.86-0.205.17
2026-07-21UTHR-49.03-0.205.17
2026-07-22UTHR-49.13-0.205.17
2026-07-23UTHR-49.30-0.205.17
2026-07-24UTHR-49.46-0.205.17
2026-07-27UTHR-49.79-0.335.10
2026-07-28UTHR-49.95-0.335.10
2026-07-29UTHR-49.34-0.335.10
2026-07-30UTHR-49.51-0.335.10
2026-07-31UTHR-49.43-0.335.10
2026-08-03UTHR-49.60-0.565.10
2026-08-04UTHR-49.37-0.565.10
2026-08-05UTHR-49.56-0.565.10
2026-08-06UTHR-49.86-0.565.10
2026-08-07UTHR-49.86-0.565.10
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

7.27

Avg. EPS Est. Current Quarter

7

Avg. EPS Est. Next Quarter

7.05

Insider Transactions

-49.86

Institutional Transactions

-0.56

Beta

0.56

Average Sales Estimate Current Quarter

818

Average Sales Estimate Next Quarter

832

Fair Value

534.82

Quality Score

100

Growth Score

93

Sentiment Score

94

Actual DrawDown %

11.6

Max Drawdown 5-Year %

-33

Target Price

664.33

P/E

19.27

Forward P/E

18.59

PEG

2.41

P/S

7.33

P/B

3.59

P/Free Cash Flow

21.21

EPS

27.96

Average EPS Est. Cur. Y​

26.92

EPS Next Y. (Est.)

31.51

Target Price Estimates Raised

1

Target Price Estimates Lowered

1

Profit Margin

41.56

Relative Volume

1.94

Return on Equity vs Sector %

-6.8

Return on Equity vs Industry %

13.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

-0.39

EBIT Estimation

UTHR Healthcare
$538.84
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
8/20
Pullback
11/25
Volume
3/15
Valuation
12/20
TP/AR
4/10
Options
7/10
RSI
55
Range 1M
60%
Sup Dist
3.7%
🚀
Momentum Growth
Ride accelerating trends
N/A
34 /100
WEAK
Momentum
5/25
Growth
11/30
Estimates
8/20
Inst/Vol
4/15
Options
6/10
EPS Yr
-6.1%
EPS NY
10.8%
52W%
76.3%
💎
Long-Term Value
Quality companies, undervalued
48 /100
WEAK
🟡 HOLD +18.8% upside
Quality
25/30
Valuation
6/30
Growth
8/25
Stability
7/10
LT Trend
2/5
Upside
+18.8%
Quality
100
MoS
-1%
UTHR — P/E HistoricalBiotechnology
United Therapeutics Corporation
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1400
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
UTHR

Latest News

Caricamento notizie per UTHR
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading